Pharmacologically Triggered Migraine Without Aura and Neuroimaging
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and
ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental
questions of migraine, which remains to be elucidated, is the mechanism behind the generation
of migraine attacks.
The investigators will use calcitonin gene-related peptide (CGRP) and sildenafil as
pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to
investigate the attack initiating pathophysiology.
Both substances have previously been administered to healthy participants and migraine
without aura patients, inducing headache and migraine-like-attacks.
The investigators hope to contribute with novelty to the current understanding of the
migraine pathophysiology and development of more efficient treatment of migraine.